Clinical Trial: Type III Dysbetalipoproteinemia
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: An 18-week, Randomized, Multicenter, Phase 3b, Double-blind, Crossover Study, Followed by an 18-week Open-Label Period to Evaluate the Efficacy & Safety of the Lipid-Regulating Agents, Rosuvastati
Brief Summary: Evaluation of the efficacy of rosuvastatin 10mg, rosuvastatin 20mg and pravastatin 40mg in subjects with dysbetalipoproteinemia.
Detailed Summary:
Sponsor: AstraZeneca
Current Primary Outcome: Percent change from baseline in non-HDL-C after 6 weeks of treatment at a given dose during the 18-week randomized crossover period.
Original Primary Outcome: Same as current
Current Secondary Outcome: Efficacy of once daily treatment with rosuvastatin 10mg, rosuvastatin 20mg and provastatin 40mg in subjects with dysbetalipoproteinemia after 6 weeks of treatment at any given dose during the 18-week randomized crossover period.
Original Secondary Outcome: Same as current
Information By: AstraZeneca
Dates:
Date Received: September 21, 2005
Date Started: February 2005
Date Completion:
Last Updated: November 18, 2010
Last Verified: November 2010